Skip to main content

Analyst says sell Abbott after stock 'Overreacted' to COVID-19 opportunity

Goldman says competitors have steadily diminished Abbott's early advantage with their own approvals.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.